BHI
logo
  • Health Plans
    • Transparency Analytics
    • Plan Performance Analytics
    • Provider Analytics
    • Employer Analytics
    • Health Equity
    • Risk Adjustment
  • Real-World Evidence Generation
  • Resources
  • About
    • Company
    • Leadership
  • Careers
  • Contact Us
  • Subscribe

JUST RELEASED

Real-World Trends in GLP-1 Prescribing and Treatment Persistence for Weight Management

Millions of Americans struggle with obesity, which can lead to substantial health risks and disease. GLP-1 drugs offer a promising treatment for weight loss and improved health. But a key question is whether patients stick with the drug long enough to benefit. This study performed on behalf of the Blue Cross Blue Shield Association explores if people prescribed GLP-1s for weight loss are giving up on treatment too soon.

Millions of Americans struggle with obesity, which can lead to substantial health risks and disease. GLP-1 drugs offer a promising treatment for weight loss and improved health. But a key question is whether patients stick with the drug long enough to benefit. This study performed on behalf of the Blue Cross Blue Shield Association explores if people prescribed GLP-1s for weight loss are giving up on treatment too soon.

Read the Issue Brief

Sign up to receive updates from BHI

Subscribe
Hide filtersShow filters
× Close
  • Benchmarking
  • Boost Your Skills
  • COVID-19
  • Chronic disease management
  • Episode of Care Grouper
  • HITRUST
  • National Benchmarking
  • Physician performance
  • Population Advyzer
  • Predictive analytics
  • Prescription drugs
  • Price transparency
  • QE
  • REL data
  • Real-world data (RWD)
  • Risk Adjustment
  • Risk scoring
  • Transparency Analytics
  • artificial intelligence
  • behavioral health
  • cost transparency
  • employer analytics and reporting
  • health equity
  • hospital outpatient care
  • machine learning
  • medical device
  • real-world evidence (RWE)
  • site-neutral
  • telehealth
  • value-based care
  • whyzen analytics

Clear all Apply

Blog

Real-World Data and Medical Device Strategies: What You Should Know

News

Blue Health Intelligence Appoints Bob Darin as Chief Executive Officer

Webinars

How to Model At-Home COVID-19 Tests, New Sheets for Net Trend and Variance

Blog

National Benchmarks are Broadening Employer Groups’ Perspective on COVID-19

Webinars

How to Import User-Generated Data, Customize Color Palettes, and Report on COVID-19

Blog

COVID-19 Challenges Continue: How Plans Can Now Track the At-Home Test Benefit

Reports

QE Report 2021: Examining the Relationship Between Socioeconomic Factors and Preventable Diabetes- and Hypertension-related Inpatient Admissions

News

BHI’s QE Report Confirms Health Inequities Contribute to Diabetes-Related Admissions

News

BHI Achieves HITRUST CSF® Certification for Information Security of Three Technologies

  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 7

© 2024 Blue Health Intelligence. Blue Health Intelligence (BHI) is a trade name of Health Intelligence Company LLC, an independent licensee of the Blue Cross Blue Shield Association.

Privacy Preference Center

Privacy Preferences